News

Cutting Edge in Medical Management of Cutaneous Oncology

The advent of a molecular targeted therapy is changing the therapeutic landscape for these diseases, with an increased therapeutic index and, in many cases, with a more tolerable toxicity profile.


 

Kim Chong, MD, Adil Daud, MD, Susana Ortiz-Urda, MD, PhD, and Sarah T. Arron, MD, PhD; for the UCSF High Risk Skin Cancer Program

Traditional chemotherapy has resulted in only a modest response, if any, for the 3 most common cutaneous malignancies of basal cell carcinoma, squamous cell carcinoma, and melanoma. Recent advances in understanding of the defects in the pathways driving tumorigenesis have changed the way that we think of these cancers and paved the way to targeted therapy for specific tumors. In this review, we will introduce the novel systemic treatments currently available for these cancers in the context of what is understood about the tumor pathogenesis. We will also introduce ongoing studies that will hopefully broaden our options for highly effective and tolerable treatment.

*For a PDF of the full article, click on the link to the left of this introduction.

Recommended Reading

USPSTF: Counsel Kids, Young Adults on Sun Exposure
MDedge Dermatology
CDC: Indoor Tanning, Sunburns Still Common in Young Adults
MDedge Dermatology
Photodamage Effectively Treated With Quasi-Ablative Approach
MDedge Dermatology
FDA Delays Sunscreen Rule by 6 Months
MDedge Dermatology
Environmental Working Group Releases Sunscreen Ranking
MDedge Dermatology
BRAF-Plus-MEK Inhibition Slows Melanoma
MDedge Dermatology
SCREEN: Melanoma Deaths Reduced by Half in Largest Study Ever
MDedge Dermatology
Dermatology Societies Publish Appropriate Use Criteria for Mohs
MDedge Dermatology
Update on the Earth’s Natural Sunscreen
MDedge Dermatology
Development of Squamous Cell Carcinoma on an Inflammatory Linear Verrucous Epidermal Nevus in the Genital Area
MDedge Dermatology